The UK’s Veterinary Medicines Directorate (VMD) has announced the launch of a new Veterinary Medicines Packaging Surveillance Scheme, set to come into force on 2 February 2026. The initiative marks a significant shift in how packaging compliance for veterinary medicines is assessed in the UK, moving from a predominantly pre-market model to a post-market, risk-based surveillance approach.
Under the new scheme, the VMD will conduct quarterly checks on selected veterinary medicines already available on the market. Products will be sourced directly from wholesalers and assessed to verify that all packaging components (including labels, leaflets and outer packaging) fully align with the approved product information and QRD standards. The objective is to ensure that packaging in real-world circulation remains compliant throughout a product’s lifecycle.
The results of each quarterly assessment will be shared with the relevant Market Authorisation Holder (MAH) during the same review period. Where issues are identified, the regulatory response will be proportionate to the severity of the non-compliance. Minor deviations may simply require corrections at the next regulatory opportunity, while more serious issues could trigger formal variation procedures or, in exceptional cases, be treated as a product defect.
A key consequence of the new surveillance model is a revision of mock-up submission requirements. From February 2026, mock-ups will no longer be required for certain regulatory procedures, including G.I.18 Variations Requiring Assessment and new Marketing Authorisation applications. The VMD will instead rely more heavily on post-market checks to ensure packaging accuracy and consistency.
Mock-up assessments will still be requested in specific situations, such as the first introduction of packaging prior to marketing, joint regulatory assessments with international partners, or when significant design or layout changes are proposed that are not directly linked to updates in the Summary of Product Characteristics. In these cases, companies will only need to submit mock-ups for the smallest marketed pack size.
The new scheme reflects a broader regulatory trend toward streamlined oversight and reduced administrative burden, while maintaining high standards of safety, clarity and traceability in veterinary medicines packaging. For manufacturers and packaging suppliers, it signals a growing emphasis on ongoing compliance in market conditions, rather than approval-driven checks alone.
As regulatory frameworks continue to evolve, packaging accuracy and lifecycle management are becoming central pillars of veterinary medicines compliance in the UK.
